
Novo Nordisk A/S
CSE:NOVO B

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Realty Income Corp
NYSE:O
|
Real Estate
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
Media
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
616.3852
1 028
|
Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Realty Income Corp
NYSE:O
|
US |
![]() |
Walt Disney Co
NYSE:DIS
|
US |
![]() |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.

Intrinsic Value
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. [ Read More ]
The intrinsic value of one
NOVO B
stock under the Base Case scenario is
hidden
DKK.
Compared to the current market price of 899.1 DKK,
Novo Nordisk A/S
is
hidden
.
Valuation Backtest
Novo Nordisk A/S
Run backtest to discover the historical profit from buying and selling
NOVO B
based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis

Balance Sheet Decomposition
Novo Nordisk A/S
Current Assets | 116.4B |
Cash & Short-Term Investments | 9.3B |
Receivables | 71.8B |
Other Current Assets | 35.4B |
Non-Current Assets | 182.5B |
Long-Term Investments | 1.7B |
PP&E | 98.2B |
Intangibles | 59.6B |
Other Non-Current Assets | 23B |
Current Liabilities | 165.6B |
Accounts Payable | 13B |
Other Current Liabilities | 152.6B |
Non-Current Liabilities | 34.4B |
Long-Term Debt | 16.8B |
Other Non-Current Liabilities | 17.6B |
Earnings Waterfall
Novo Nordisk A/S
Revenue
|
244.2B
DKK
|
Cost of Revenue
|
-37.5B
DKK
|
Gross Profit
|
206.7B
DKK
|
Operating Expenses
|
-97.3B
DKK
|
Operating Income
|
109.4B
DKK
|
Other Expenses
|
-20.1B
DKK
|
Net Income
|
89.3B
DKK
|
Free Cash Flow Analysis
Novo Nordisk A/S
DKK | |
Free Cash Flow | DKK |
In Q1 2024, Novo Nordisk achieved a 24% increase in sales and a 30% rise in operating profit. The company raised its full-year outlook, driven by solid demand for its diabetes and obesity treatments, particularly GLP-1 therapies. North American sales grew by 35%, while international operations saw an 11% increase. Notably, obesity care sales soared by 42%, led by Wegovy. The company also reported a 32% rise in carbon emissions due to higher capital expenditure. Commitments to sustainability included a higher percentage of women in senior leadership roles and significant R&D milestones, such as the approval of the Wegovy label expansion in the U.S.
What is Earnings Call?
NOVO B Profitability Score
Profitability Due Diligence
Novo Nordisk A/S's profitability score is hidden . The higher the profitability score, the more profitable the company is.

Score
Novo Nordisk A/S's profitability score is hidden . The higher the profitability score, the more profitable the company is.
NOVO B Solvency Score
Solvency Due Diligence
Novo Nordisk A/S's solvency score is hidden . The higher the solvency score, the more solvent the company is.

Score
Novo Nordisk A/S's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NOVO B Price Targets Summary
Novo Nordisk A/S
According to Wall Street analysts, the average 1-year price target for
NOVO B
is 963.15 DKK
.
Shareholder Yield
Current shareholder yield for NOVO B is
hidden
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
NOVO B Price
Novo Nordisk A/S
Average Annual Return | 35.12% |
Standard Deviation of Annual Returns | 25.69% |
Max Drawdown | -19% |
Market Capitalization | 4T DKK |
Shares Outstanding | 4 461 908 793 |
Percentage of Shares Shorted |
N/A
|
Company Profile


Country
Industry
Market Cap
Dividend Yield
Description
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Officers
The intrinsic value of one
NOVO B
stock under the Base Case scenario is
hidden
DKK.
Compared to the current market price of 899.1 DKK,
Novo Nordisk A/S
is
hidden
.